Ambrx Announces First Patient Dosed In A Phase 1 Trial For ARX517, An ADC In Development To Treat PSMA Expressing Tumors
SAN DIEGO–(BUSINESS WIRE)–Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the first patient has been dosed…